Skip to content
ODReference

Plaquenil Dose and Retinopathy Risk Calculator

Calculate daily mg/kg, identify AAO 2016 risk factors, and determine screening frequency

Calculate Plaquenil Risk

Patient Parameters

Weight, Dosing, and Duration

Weight unit
Type numbers to set the value. Press Enter to commit. Press Escape to clear typed input.
Type numbers to set the value. Press Enter to commit. Press Escape to clear typed input.
Type numbers to set the value. Press Enter to commit. Press Escape to clear typed input.

Additional Factors

Renal Function
Concomitant Tamoxifen Use
Pre-existing Macular or Retinal Disease
Patient of Asian Descent

Plaquenil (Hydroxychloroquine) Dosing and Screening Overview

Why the 2016 AAO guideline matters

The 2016 American Academy of Ophthalmology (AAO) guideline on hydroxychloroquine screening (Marmor et al.) shifted the primary dose threshold from ≤ 6.5 mg/kg of ideal body weight to ≤ 5 mg/kg of real body weight. The change was driven by real-world data showing that ideal-weight dosing systematically under-estimated mg/kg exposure in overweight patients, putting them at higher-than-recognized risk of retinal toxicity. In practice, a 400 mg/day dose is safe by the new threshold only in patients who weigh roughly 80 kg (176 lb) or more. Any patient below that weight on 400 mg/day is exceeding the recommended daily dose and should be flagged for potential dose adjustment.

Major risk factors for hydroxychloroquine retinopathy

The AAO 2016 guideline identifies five major risk factors that increase the likelihood of retinal toxicity. Any one of these shifts a patient from routine monitoring to annual screening regardless of duration:

  • High daily dose: > 5 mg/kg of real body weight.
  • Long duration of use: ≥ 5 years at an allowed dose.
  • Renal disease: reduced clearance raises effective exposure (eGFR < 60 is the commonly used threshold).
  • Concomitant tamoxifen use: tamoxifen is itself associated with retinal toxicity and was identified by Melles and Marmor as an independent risk factor for hydroxychloroquine retinopathy with an odds ratio of approximately 4.6 in their 2,361-patient cohort. Annual screening should begin from the start of co-therapy regardless of duration, and the daily mg/kg warrants direct discussion with the prescribing oncologist if it also exceeds 5.
  • Pre-existing macular or retinal disease: any maculopathy makes toxicity earlier to develop and harder to detect.

Of these, daily mg/kg is the single most important modifiable risk factor. Duration alone drives timing of screening but is not itself an elevation of per-year risk when dose is appropriate.

Cumulative dose and long-term monitoring

The pre-2016 AAO guideline used a cumulative dose threshold of 1000 g as a primary risk benchmark, beyond which retinopathy risk was considered significantly elevated. The 2016 update shifted primary stratification to daily mg/kg of real body weight because cumulative thresholds systematically under-flagged thin patients on appropriate total daily doses while over-flagging large patients on the same regimen. The 1000 g figure has not disappeared from the literature, though — it remains a useful long-term reference and is still worth tracking in the chart alongside daily mg/kg.

At the two most common maintenance regimens, a patient on 400 mg/day reaches 1000 g in approximately 6.8 years, and a patient on 200 mg/day in approximately 13.7 years. In practice, this means any patient on 400 mg/day approaches the cumulative threshold around the same time the 5-year duration trigger kicks in for annual screening — so the two cutoffs reinforce each other. Patients on long-term low-dose therapy are the more common miss: they can quietly accumulate a high total exposure over a decade-plus of compliant use without ever exceeding the daily mg/kg threshold, and tracking total grams catches that pattern earlier than dose alone would.

Population-level retinopathy risk by daily-dose tier and duration of use is characterized in the Melles & Marmor 2014 retrospective cohort (JAMA Ophthalmology, n = 2,361) — the source for the risk-reference table on this page. Their data stratifies risk by daily mg/kg and years of use; renal impairment, tamoxifen, and pre-existing macular disease can each shift individual risk above the cohort baseline.

AAO screening protocol

The AAO 2016 schedule has three tiers:

  • Baseline: fundus examination within the first year of starting hydroxychloroquine. Objective testing is recommended at baseline only if pre-existing macular disease is present or suspected.
  • Years 1–5 with no major risk factors: no routine annual screening required. Re-screen at year 5.
  • Year 5 and beyond: annual screening with the full test battery, regardless of dose.
  • Any major risk factor present: annual screening begins immediately, regardless of duration.

The recommended test battery is a 10-2 automated visual field for non-Asian patients (parafoveal pattern is typical), spectral-domain OCT (SD-OCT) of the macula, and either fundus autofluorescence (FAF) or multifocal electroretinography (mfERG) for objective confirmation. In patients of Asian descent, a 24-2 or 30-2 visual field is recommended because toxicity often presents with a pericentral rather than parafoveal pattern and can be missed on 10-2 alone.

Clinical pearls

  • Bull's eye maculopathy is a late finding. By the time it is visible on fundus exam, significant and often irreversible photoreceptor damage has already occurred.
  • OCT "flying saucer" sign. Loss of the parafoveal ellipsoid zone with preservation of the foveal ellipsoid creates a characteristic appearance on SD-OCT and is an early structural sign of toxicity.
  • FAF parafoveal hyperautofluorescence can precede measurable photoreceptor loss and is a useful early objective marker.
  • Pericentral pattern in Asian patients. A normal 10-2 does not rule out toxicity in this population — if there is any clinical suspicion or subjective symptom, a 24-2 or 30-2 should be performed.
  • Toxicity can progress after discontinuation. Retinal damage may worsen for months after the medication is stopped, which is why early detection matters.
  • Subjective symptoms are unreliable. Most patients with early toxicity are asymptomatic; by the time they notice a paracentral scotoma, structural damage is typically well established.

Plaquenil Screening FAQs

What is the maximum safe dose of Plaquenil?

The 2016 AAO guideline recommends a maximum daily dose of 5 mg/kg of real body weight for hydroxychloroquine. A 400 mg/day dose is safe by this threshold only in patients weighing approximately 80 kg (176 lb) or more. Patients below that weight on 400 mg/day are exceeding the recommended daily dose and should be flagged for potential dose adjustment.

Is 200 mg of Plaquenil safe?

A 200 mg/day dose stays within the AAO 5 mg/kg of real body weight threshold for any patient weighing approximately 40 kg (88 lb) or more — which covers essentially all adult patients. It is a common maintenance regimen for SLE, RA, and Sjögren syndrome, and is the most straightforward way to bring an over-dosed patient back into compliance with the 2016 guideline. Duration of use, renal function, concurrent tamoxifen, and pre-existing macular disease still drive screening frequency independent of daily mg/kg.

At what body weight is 400 mg of Plaquenil safe?

A 400 mg/day dose stays within the AAO 5 mg/kg of real body weight threshold only in patients who weigh 80 kg (176 lb) or more. Below that weight, 400 mg/day exceeds the recommended daily dose and is the most common scenario flagged for prescriber communication. Typical alternatives are 300 mg/day or alternate-day dosing — many rheumatologists are receptive to a reduction once the calculated mg/kg is shown alongside the AAO threshold and the maximum safe dose at the patient's current weight.

Is Plaquenil dose based on ideal body weight or actual body weight?

The 2016 AAO guideline uses real (actual) body weight, not ideal body weight. The change from the prior ideal-weight standard was driven by real-world data showing that ideal-weight dosing systematically underestimated mg/kg exposure in overweight patients and put them at higher-than-recognized risk of retinal toxicity.

How long does it take for Plaquenil to cause retinopathy?

Retinal toxicity is rare before 5 years of use at doses ≤ 5 mg/kg/day. With appropriate dosing, the cumulative risk remains under 1% at 5 years, rising to approximately 2% at 10 years and ~20% after 20 years of continuous use. Higher daily doses, impaired renal clearance, concurrent tamoxifen, and pre-existing macular disease all shorten the time to toxicity.

What is the cumulative dose limit for Plaquenil?

The pre-2016 AAO guideline used a cumulative dose threshold of 1000 g, beyond which retinopathy risk was considered significantly elevated. The 2016 update shifted primary risk stratification to daily mg/kg of real body weight rather than total cumulative exposure, but the 1000 g figure is still a useful clinical reference: at 400 mg/day, a patient reaches 1000 g in roughly 6.8 years; at 200 mg/day, in roughly 13.7 years. Cumulative exposure should be tracked alongside daily mg/kg, especially in long-term users on an otherwise appropriate dose.

What tests are used for Plaquenil screening?

The AAO-recommended test battery is a 10-2 visual field (or 24-2 / 30-2 in patients of Asian descent), SD-OCT of the macula, and either fundus autofluorescence (FAF) or multifocal ERG (mfERG) for objective confirmation. Subjective symptoms and fundus appearance are unreliable for early detection — most patients with early toxicity are asymptomatic and have a normal-appearing fundus.

Do I need a screening exam if I just started Plaquenil?

Yes — a baseline fundus examination is recommended within the first year of starting hydroxychloroquine. Objective testing (OCT, VF, FAF/mfERG) is not routinely required at baseline unless pre-existing macular disease is present or suspected, in which case baseline objective testing establishes a reference for future comparisons. Annual screening is not required before year 5 in the absence of major risk factors.

Does Plaquenil retinopathy reverse if the medication is stopped?

Early-stage toxicity — identified before bull's eye maculopathy is visible — typically stabilizes or only slowly progresses after discontinuation. Established toxicity with visible bull's eye maculopathy is generally permanent and can continue to progress for months or even years after the drug is stopped. This is the clinical argument for aggressive early screening: the window for intervention closes before the patient is symptomatic.

Why is the 10-2 visual field used, and when is 24-2 better?

The 10-2 visual field samples the central 10 degrees densely and is well suited to detect the parafoveal pattern of toxicity that is typical in non-Asian patients. In patients of Asian descent, toxicity often presents with a pericentral pattern outside the central 10 degrees, which a 10-2 can miss. For this population, a 24-2 or 30-2 is the more appropriate default — and in any patient with clinical suspicion or a subjective paracentral scotoma, a wider field should be obtained regardless of ethnicity.